Note:  Dr. Edward Hutt, MD, worked for PPTA as Director Public Affairs
from 2000 to 2004
Abstract: Plasma products are used to treat a number of serious inherited
disorders, of which the best known is haemophilia. However, a number of other
conditions exist at a similar frequency in the population but are much less
well known: Alpha 1-Antitrypsin (AAT) deficiency or 'Alpha-1' is one of these.
Alpha-1 is a life-threatening genetic disorder in some individuals who
demonstrate clinical evidence of emphysema. Left untreated, this form of
emphysema can be fatal. Historically, people with Alpha-1 have been concerned
with the critical short supply of the therapy. Recent product approvals will
provide the desperately needed product, so people with Alpha-1 can focus more
on their lives and less on when their therapy will be available.